Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192.SS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE1000055W8

Price
60.05 CNY
Market cap
27.69 bn CNY
P/E (2025)
–
P/S (2025)
34.57
Dividend yield
0.00 %
Net margin
-95.37 %
Return on equity (ROE)
-59.05 %
Return on assets (ROA)
-25.45 %

Dizal (Jiangsu) Pharmaceutical Co. Ltd. A financials

Fiscal year20242025
Revenue359.90 m CNY801.14 m CNY
Gross profit350.58 m CNY766.91 m CNY
Operating income-932.84 m CNY-760.33 m CNY
EBIT-916.90 m CNY-735.91 m CNY
Net income-845.96 m CNY-764.05 m CNY
Diluted EPS – continuing operations-2.03 CNY-1.66 CNY

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Dizal (Jiangsu) Pharmaceutical Co. Ltd. A

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. Dizal (Jiangsu) Pharmaceutical Co., Ltd. was founded in 2017 and is based in Shanghai, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.